Drugs / CIML NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04024761 | Aug 2019 → Dec 2026 expected | acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIML NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04024761 ↗ |
| Action | Deplete | “CIML NK cells have enhanced ability to recognize and kill leukemia targets” NCT04024761 ↗ |
| Modality | Cell therapy | “adoptively transferred cytokine-induced memory-like (CIML) NK cells” PMID 35349491 ↗ Jun 2022 |
| Route | Intravenous | “CIML NK cells will be administered intravenously on day 0.” NCT04024761 ↗ |